Further, our data showed that pharmacological inhibition of USP14 with the FDA approved inhibitor VLX1570 [13, 22–26] was accompanied by a reduction of the cell viability of endometrial cancer cells with resistance to carboplatin. This evidence concerns the gene USP14 and endometrial cancer.